Sovereign mRNA Manufacturing and Australia’s Pandemic Preparedness Strategy

Building a Domestic Shield Against Future Health Threats

Australia’s capacity to manufacture mRNA vaccines at scale has undergone a fundamental transformation. The Moderna Technology Centre – Melbourne (MTC-M), located at Monash University’s Clayton campus, is now the first commercial-scale mRNA manufacturing facility in the Southern Hemisphere, with capacity to produce up to 100 million vaccine doses per year for diseases including COVID-19, influenza, and RSV.

Officially opened in December 2024 and granted its full Good Manufacturing Practice (GMP) licence from the Therapeutic Goods Administration (TGA) in August 2025, the MTC-M is the only Moderna manufacturing site globally with end-to-end mRNA manufacturing capabilities—from drug substance production through to fill-and-finish and packaging onsite, ready for distribution across Australia and internationally.

The Economics of Sovereign Capability

The strategic rationale for sovereign mRNA manufacturing extends beyond health security. An Oxford Economics report, Australia’s mRNA Advantage: Jobs, Health and Economic Resilience, estimates that the Moderna facility could save Australia $4.8 billion in future pandemic costs over the next 30 years, based on an almost 2% likelihood of a pandemic occurring annually.

This economic calculus reflects the high cost of reliance on international supply chains during global health emergencies. During the COVID-19 pandemic, Australia experienced vaccine delivery delays and supply uncertainty as manufacturing nations prioritised domestic needs. Sovereign manufacturing capability transforms Australia from a price-taker in global vaccine markets to a nation with guaranteed access to critical medical countermeasures.

The Victorian Government’s partnership with Moderna involves a range of initiatives to build the local mRNA ecosystem. Moderna’s Regional Research Centre for Respiratory Medicines and Tropical Diseases, launched in 2023, drives collaboration with local research institutions to develop next-generation mRNA vaccines and medicines. The first partnership through the Centre is the Monash-Moderna Quantitative Pharmacology Accelerator, which uses advanced computer models to make mRNA medicine development safer and more efficient.

BioNTech’s Clinical-Scale Facility: Expanding the Ecosystem

Victoria’s mRNA ambitions extend beyond population-scale manufacturing. BioNTech is constructing a clinical-scale mRNA manufacturing facility at La Trobe University’s Bundoora campus, incorporating two BioNTainer manufacturing units from Germany—named Wirrarap and Boordup in Woi-wurrung language. The facility is expected to be completed by the end of 2026.

The BioNTainer units are modular manufacturing systems deployed in only two locations globally outside Germany, making Victoria one of only two global locations to host this technology. The facility is an anchor tenant of La Trobe University’s $5 billion University City precinct, supporting up to 1,200 jobs in the wider industry over the next 10 years.

This dual-track approach—population-scale manufacturing through Moderna and clinical-scale innovation through BioNTech—creates a comprehensive mRNA ecosystem spanning research, clinical development, and commercial production.

The NSW RNA Research and Manufacturing Facility

Complementing Victoria’s manufacturing capacity, New South Wales has invested in upstream research and development infrastructure. The $96 million RNA Research and Manufacturing Facility at Macquarie University’s Innovation Precinct officially opened in April 2026, positioning NSW as a global leader in RNA research.

The NSW Government has also launched the RNA Pipeline Grants program, a $6 million initiative supporting startups developing innovative RNA-based therapies, vaccines, and technologies. Two recipients illustrate the breadth of innovation: Platypus Bio is developing “TRICK” (Trigger RNA-Induced Cell Killing), a highly targeted RNA therapeutic that activates only inside cancer cells carrying specific harmful RNA mutation signals; and Vaxosome is developing a multiplexed mRNA TB vaccine to address limitations in current tuberculosis treatment.

These programs are part of the NSW Government’s $119 million RNA R&D Initiative, creating a pipeline of RNA-based products that can be manufactured at the new facility.

Onshore Manufacturing as Critical National Infrastructure

The strategic framing of mRNA manufacturing has evolved beyond public health to encompass advanced manufacturing and economic resilience. Onshore mRNA production is increasingly viewed as critical national infrastructure, strengthening Australia’s pandemic preparedness while building sovereign capability in a platform technology with applications beyond vaccines—including cancer immunotherapies, protein replacement therapies, and rare disease treatments.

This framing has attracted bipartisan political support. Victorian Minister Dimopoulos noted that the BioNTech facility installation supports up to 1,200 jobs, positioning Victoria as a global leader in mRNA vaccine manufacturing. The concentration of mRNA manufacturing capability in Victoria—home to two of the world’s leading mRNA vaccine developers, Moderna and BioNTech—creates agglomeration effects that attract talent, suppliers, and research partnerships.

Challenges: Workforce, Supply Chain, and Commercial Viability

Building sovereign mRNA capability requires more than physical infrastructure. A skilled workforce in mRNA manufacturing, quality assurance, and regulatory affairs is essential. The facilities create demand for specialised talent that Australia’s education and training systems must supply.

Supply chain dependencies remain a consideration. While fill-and-finish is conducted domestically, critical inputs such as enzymes, nucleotides, and lipid nanoparticles may still be sourced internationally. Developing a fully sovereign mRNA supply chain would require investment in upstream chemical and biological manufacturing—a longer-term proposition.

Commercial viability for the facilities depends on utilisation rates beyond pandemic response. The ability to manufacture mRNA vaccines and therapeutics for endemic diseases—influenza, RSV, and potentially cancer vaccines—is essential for sustainable operations. Moderna’s Regional Research Centre and BioNTech’s R&D facility are designed to generate a pipeline of products that can utilise the manufacturing capacity.

A Platform for Future Innovation

The establishment of mRNA manufacturing infrastructure in Australia creates a platform for broader innovation. The technology’s versatility—encoding any protein of interest—opens applications across infectious disease, oncology, autoimmune conditions, and rare genetic disorders. Australian researchers now have access to domestic manufacturing capability for clinical trial materials, reducing reliance on overseas contract manufacturers and accelerating translation from discovery to clinical testing.

The mRNA ecosystem being built in Victoria and NSW represents one of the most significant investments in Australian biotechnology infrastructure in decades. Its success will depend on sustained commitment from government, industry, and research institutions to populate the pipeline with products that justify the capacity.